Prostate Cancer Update

Featuring an interview with Dr Rana R McKay, including the following topics:
Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
Takeaways from the Phase III EMBARK study (19:36)
Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:
Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications

Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics:
Introduction: Life After Radical Cystectomy (0:00)
Muscle-Invasive Bladder Cancer — Prof Powles (9:15)
Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49)

CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:
Introduction (0:00)
Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)
Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:
Introduction (0:00)
Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications